{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:24:23Z","timestamp":1791393863786,"version":"4.3.3"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1038\/ajg.2011.72","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T11:40:38Z","timestamp":1300189238000},"page":"661-673","source":"Crossref","is-referenced-by-count":493,"title":["Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.14309","volume":"106","author":[{"given":"Khurram J","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Ullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Abadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Talley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moayyedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210306","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00004836-198806000-00012","article-title":"Historical aspects of inflammatory bowel disease.","volume":"10","author":"Krisner","year":"1988","journal-title":"J Clin Gastroenterol"},{"key":"R2-14-20210306","first-page":"1058","article-title":"Chronic interstitial enteritis.","volume":"25","author":"Dalziel","year":"1913","journal-title":"BMJ"},{"key":"R3-14-20210306","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/gut.2004.055889","article-title":"Does Mycobacterium avium subspecies paratuberculosis cause Crohns disease?","volume":"54","author":"Sartor","year":"2005","journal-title":"Gut"},{"key":"R4-14-20210306","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease.","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-14-20210306","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/IAI.66.11.5224-5231.1998","article-title":"Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice.","volume":"66","author":"Sellon","year":"1998","journal-title":"Infect Immun"},{"key":"R6-14-20210306","first-page":"454","article-title":"A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.","volume":"92","author":"Mantzaris","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"R7-14-20210306","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0016-5085(98)70076-9","article-title":"Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study.","volume":"115","author":"Turunen","year":"1998","journal-title":"Gastroenterology"},{"key":"R8-14-20210306","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1572-0241.2000.01842.x","article-title":"A meta-analysis of antimycobacterial therapy for Crohns disease.","volume":"95","author":"Borgaonkar","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R10-14-20210306","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1086\/649923","article-title":"Long-term antibiotic treatment for Crohns disease: systematic review and meta-analysis of placebo-controlled trials.","volume":"50","author":"Feller","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R11-14-20210306","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1007\/s10620-007-9760-1","article-title":"A meta-analysis of antibiotic therapy for active ulcerative colitis.","volume":"52","author":"Rahimi","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R13-14-20210306","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R14-14-20210306","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R15-14-20210306","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R16-14-20210306","first-page":"513","article-title":"Antimycobacterial therapy in Crohns disease: results of a controlled, double-blind trial with a multiple antibiotic regimen.","volume":"89","author":"Prantera","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"R17-14-20210306","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2007.03.031","article-title":"Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohns disease.","volume":"132","author":"Selby","year":"2007","journal-title":"Gastroenterology"},{"key":"R18-14-20210306","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/gast.2002.34225","article-title":"Combined budesonide and antibiotic therapy for active Crohns disease: a randomized controlled trial.","volume":"123","author":"Steinhart","year":"2002","journal-title":"Gastroenterology"},{"key":"R19-14-20210306","doi-asserted-by":"crossref","first-page":"A826","DOI":"10.1016\/0016-5085(95)27612-2","article-title":"Prolonged remission in Crohns disease following therapy for mycobacterium paratuberculosis infection.","volume":"108","author":"Graham","year":"1995","journal-title":"Gastroenterology"},{"key":"R20-14-20210306","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1365-2036.2008.03661.x","article-title":"Clinical trial: randomized study of clarithromycin versus placebo in active Crohns disease.","volume":"27","author":"Leiper","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-14-20210306","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/gut.32.9.1071","article-title":"Double blind, placebo controlled trial of metronidazole in Crohns disease.","volume":"32","author":"Sutherland","year":"1991","journal-title":"Gut"},{"key":"R22-14-20210306","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00054725-200201000-00002","article-title":"Preliminary study of ciprofloxacin in active Crohns disease.","volume":"8","author":"Arnold","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"R23-14-20210306","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01298873","article-title":"Controlled trial of antimycobacterial therapy in Crohns disease. Clofazimine versus placebo.","volume":"36","author":"Afdhal","year":"1991","journal-title":"Dig Dis Sci"},{"key":"R24-14-20210306","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1365-2036.2006.02879.x","article-title":"Antibiotic treatment of Crohns disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.","volume":"23","author":"Prantera","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-14-20210306","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/bjs.7121","article-title":", The Topical Metronidazole in Perianal Crohns Study Group. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohns disease.","volume":"97","author":"Maeda","year":"2010","journal-title":"Br J Surg"},{"key":"R27-14-20210306","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-2036.2004.02247.x","article-title":"Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohns disease with infliximab: a double-blind placebo-controlled study.","volume":"20","author":"West","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-14-20210306","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ibd.20608","article-title":"Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohns disease: a randomized, double-blind, placebo-controlled pilot study.","volume":"15","author":"Thia","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R29-14-20210306","first-page":"43","article-title":"Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.","volume":"89","author":"Mantzaris","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"R30-14-20210306","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1080\/00365520510023648","article-title":"Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: A randomized, controlled pilot trial with long-term follow-up.","volume":"40","author":"Ohkusa","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"R31-14-20210306","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/ajg.2010.84","article-title":"Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial.","volume":"105","author":"Ohkusa","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R32-14-20210306","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/003655201750305503","article-title":"A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis.","volume":"36","author":"Mantzaris","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"R33-14-20210306","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2036.1990.tb00456.x","article-title":"The efficacy of tobramycin in the treatment of ulcerative colitis.","volume":"4","author":"Burke","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-14-20210306","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/gut.26.12.1380","article-title":"Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis.","volume":"26","author":"Dickinson","year":"1985","journal-title":"Gut"},{"key":"R35-14-20210306","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1023\/A:1026648812439","article-title":"Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial.","volume":"44","author":"Gionchetti","year":"1999","journal-title":"Dig Dis Sci"},{"key":"R36-14-20210306","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2036.1993.tb00084.x","article-title":"Oral tobramycin in ulcerative colitis: effect on maintenance of remission.","volume":"7","author":"Lobo","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-14-20210306","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02552649","article-title":"Antibiotic therapy for treatment in relapse of intestinal Crohns disease. A prospective randomized study.","volume":"28","author":"Ambrose","year":"1985","journal-title":"Dis Colon Rectum"},{"key":"R38-14-20210306","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/gut.27.10.1210","article-title":"Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.","volume":"27","author":"Chapman","year":"1986","journal-title":"Gut"},{"key":"R39-14-20210306","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1046\/j.1365-2036.2001.01099.x","article-title":"Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohns disease.","volume":"15","author":"Goodgame","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R40-14-20210306","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/gut.35.3.363","article-title":"Controlled trial of anti-tuberculous chemotherapy for two years in Crohns disease.","volume":"35","author":"Swift","year":"1994","journal-title":"Gut"},{"key":"R41-14-20210306","first-page":"245","article-title":"Controlled trial of rifabutin in Crohns disease.","volume":"46","author":"Basilisco","year":"1989","journal-title":"Curr Ther Res"},{"key":"R42-14-20210306","first-page":"A449","article-title":"Preliminary trial of clofazimine in chronic inflammatory bowel disease.","volume":"23","author":"Kelleher","year":"1982","journal-title":"Gut"},{"key":"R43-14-20210306","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2005.01.010","article-title":"Ornidazole for prophylaxis of postoperative Crohns disease recurrence: a randomized, doubleblind, placebo-controlled trial.","volume":"128","author":"Rutgeerts","year":"2005","journal-title":"Gastroenterology"},{"key":"R44-14-20210306","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/0016-5085(95)90121-3","article-title":"Controlled trial of metronidazole treatment for prevention of Crohns recurrence after ileal resection.","volume":"108","author":"Rutgeerts","year":"1995","journal-title":"Gastroenterology"},{"key":"R45-14-20210306","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/gut.25.2.203","article-title":"Controlled trial of rifampicin and ethambutol in Crohns disease.","volume":"25","author":"Shaffer","year":"1984","journal-title":"Gut"},{"key":"R46-14-20210306","first-page":"328","article-title":"An antibiotic regimen for the treatment of active Crohns disease: a randomized, controlled trial of metronidazole plus ciprofloxacin.","volume":"91","author":"Prantera","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R47-14-20210306","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000198703","article-title":"Sulphadoxine-pyrimethamine therapy in Crohns disease.","volume":"23","author":"Elliott","year":"1982","journal-title":"Digestion"},{"key":"R48-14-20210306","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/MOG.0b013e3283023be5","article-title":"Pathogenic agents in inflammatory bowel diseases.","volume":"24","author":"Pineton de Chambrun","year":"2008","journal-title":"Curr Opin Gastroenterol"},{"key":"R49-14-20210306","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1473-3099(07)70211-6","article-title":"Mycobacterium avium subspecies paratuberculosis and Crohns disease: a systematic review and meta-analysis.","volume":"7","author":"Feller","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"R50-14-20210306","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000081999","article-title":"Rifaximin, a peculiar rifamycin derivative: established and potential clinical uses outside the gastrointestinal tract.","volume":"51","author":"Pelosini","year":"2005","journal-title":"Chemotherapy"},{"key":"R51-14-20210306","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/ajg.2009.29","article-title":"Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohns disease in Swedish men.","volume":"104","author":"Schoultz","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R52-14-20210306","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/ajg.2009.315","article-title":"Low Mannan-binding lectin serum levels are associated with complicated Crohns disease and reactivity to oligomannan (ASCA).","volume":"104","author":"Schoepfer","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R53-14-20210306","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1572-0241.2007.01592.x","article-title":"Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission.","volume":"103","author":"Martinez","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R54-14-20210306","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Assessing the quality of controlled clinical trials.","volume":"323","author":"Juni","year":"2001","journal-title":"BMJ"},{"key":"R55-14-20210306","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing.","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1038\/ajg.2011.131","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T00:00:00Z","timestamp":1304467200000}}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg201172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201172","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201104000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:35:44Z","timestamp":1786541744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201104000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2011.72","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}